Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Antibody evasion of Omicron BA.2.75 is less pronounced than BA.4/5

Researchers assess the sensitivity of the SARS-CoV-2 Omicron BA.2.75 sublineage to neutralization.

9 Aug 2022

Next-generation monoclonal antibody prevents malaria

Researchers investigate the pharmacokinetics and safety of L9LS, a monoclonal antibody to prevent malaria.

9 Aug 2022

Trial evaluates sugemalimab as a consolidation treatment in patients with unresectable stage III NSCLC

The human monoclonal antibody sugemalimab is a safe and effective consolidation therapy for patients with unresectable stage III non-small cell lung cancer without disease progression after either concurrent chemoradiotherapy (cCRT) or sequential chemoradiotherapy (sCRT), according to findings presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna.

8 Aug 2022

Researchers identify mechanistic principles for engineering antibodies to enhance cadherin adhesion

Future treatments for advanced cancer could work by sticking cancer cells in place and preventing their spread around the body. A new study by researchers at the University of California, Davis, and the University of Washington shows how an antibody strengthens bonds between cells. The work is published Aug. 3 in Proceedings of the National Academy of Sciences.

5 Aug 2022

Novel fusion protein drug for Alzheimer’s disease circumvents the neurotoxic inflammatory side effects

Although Aduhelm, a monoclonal antibody targeting amyloid beta (Aβ), recently became the first US FDA approved drug for Alzheimer's disease (AD) based on its ability to decrease Aβ plaque burden in AD patients, its effect on cognitive improvement is still controversial.

4 Aug 2022

Monoclonal antibody protects U.S. adults from malaria, Phase 1 clinical trial shows

One injection of a candidate monoclonal antibody (mAb) known as L9LS was found to be safe and highly protective in U.S. adults exposed to the malaria parasite, according to results from a National Institutes of Health Phase 1 clinical trial published in The New England Journal of Medicine.

4 Aug 2022

What are the hidden sources of SARS-CoV-2 evolution?

A recent article published in Transplant Infectious Disease examined case reports on SARS-CoV-2 evolution in immunosuppressed cohorts.

2 Aug 2022

How and when do de novo SARS-CoV-2 spike mutations emerge?

Researchers evaluated viral mutations in two patients with persistent SARS-CoV-2 infection.

1 Aug 2022

The identification and characterization of an anti-SARS-CoV-2 monoclonal antibody with superior breadth and potency

A recent study published in Nature Microbiology identified a monoclonal antibody neutralizing SARS-CoV-2 Omicron variants.

28 Jul 2022

Everything you need to know about Paxlovid — especially, should you take it?

When President Joe Biden tested positive for covid-19 on July 21, his physician recommended he take the antiviral drug Paxlovid.

28 Jul 2022

Study shows the emerging Omicron sublineage BA.2.75 does not show greater immune evasion than BA.5

Researchers assessed the sensitivity of SARS-CoV-2 Omicron BA.2.75 variant to neutralizing antibodies.

27 Jul 2022

What is the association between natural killer cell dysfunction and COVID-19 disease severity?

Researchers assessed the association between natural killer cell dysfunction and COVID-19 disease severity.

20 Jul 2022

Scientists evaluate immunostimulatory glycolipid against SARS-CoV-2 infection

A new study showed that 7DW8-5, an immunostimulatory glycolipid impeded three respiratory viral infections, including SARS-CoV-2, in vivo.

18 Jul 2022

Researchers develop a rapid, specific, and accurate RT-qPCR-based method to detect and distinguish between Omicron sublineages

Researchers developed a novel, rapid and accurate qRT-PCR-based method to detect Omicron sublineages BA.1/BA.1.1 and BA.2 in patient samples.

18 Jul 2022

UC San Francisco neurologists focus on the hazards of abortion restrictions for women of reproductive age

UCSF Perspective Article Says New Ruling May Result in Increased Risk of Deaths, Disability.

14 Jul 2022

The potential of tixagevimab–cilgavimab for treating hospitalized COVID-19 patients

Scientists assessed the potential of tixagevimab–cilgavimab for treating hospitalized SARS-CoV-2 patients.

13 Jul 2022

Scientists explore antigenic imprinting in SARS-CoV-2

A recently published study compared monoclonal RBD antibody responses induced by SARS-CoV-2 Beta variant infections to antibodies induced by the ancestral virus in immunologically naive subjects.

12 Jul 2022

Monoclonal antibody treatment taken by hospitalized COVID-19 patients reduces mortality

A monoclonal antibody treatment taken by patients hospitalized with COVID-19 did not improve recovery time but did reduce deaths, according to a study published July 8 in The Lancet Respiratory Medicine.

8 Jul 2022

After 3 doses of COVID vaccine, most cancer patients retain detectable humoral immunity

In a recent study posted to the medRxiv* preprint server, researchers assessed the efficacy and durability of immune responses to the third dose of coronavirus disease 2019 (COVID-19) vaccines. They also assessed the efficacy of the fourth vaccine dose among severely immunocompromised patients with hematological malignancies.

7 Jul 2022

Novel COVID-19 antibody delivery approach advances to clinical trials

Under a Defense Advanced Research Projects Agency (DARPA) and Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) funded program, a novel COVID-19 antibody delivery approach has advanced to clinical trials.